Xenon Pharmaceuticals (XENE) to Release Quarterly Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Xenon Pharmaceuticals to announce earnings of ($1.14) per share and revenue of $1.6670 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting the consensus estimate of ($1.17). During the same period last year, the business posted ($0.83) EPS. On average, analysts expect Xenon Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Xenon Pharmaceuticals Trading Up 1.6%

XENE stock traded up $1.02 during trading on Tuesday, hitting $63.28. 170,857 shares of the company’s stock were exchanged, compared to its average volume of 1,319,490. The business has a 50-day moving average price of $59.46 and a two-hundred day moving average price of $53.64. The stock has a market capitalization of $6.12 billion, a price-to-earnings ratio of -13.47 and a beta of 0.62. Xenon Pharmaceuticals has a 52-week low of $32.78 and a 52-week high of $72.66.

Insider Buying and Selling

In other news, Director Gary Patou sold 1,322 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the sale, the director directly owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director owned 1,455 shares in the company, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.91% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Danske Bank A S purchased a new stake in shares of Xenon Pharmaceuticals in the third quarter valued at about $32,000. Kestra Advisory Services LLC acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $33,000. Osaic Holdings Inc. increased its position in Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,034 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Xenon Pharmaceuticals during the 4th quarter valued at approximately $43,000. Finally, State of Wyoming raised its stake in Xenon Pharmaceuticals by 30.4% during the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 350 shares during the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

XENE has been the topic of a number of research analyst reports. Needham & Company LLC cut their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Wall Street Zen upgraded shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Finally, Royal Bank Of Canada boosted their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $77.20.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.